High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Abroad (travel likely)RecruitingPHASE2

Conditions

Splenomegaly · Myelofibrosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Uday Popat, MD) · upopat@mdanderson.org · 713-563-0812
Contact: Principal Investigator (Uday Popat, MD)

Study leads

Uday Popat, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

BCR-JAK2 Fusion Protein Expression · Blasts 20 Percent or Less of Peripheral Blood White Cells · Blasts More Than 5 Percent of Bone Marrow Nucleated Cells

Abroad (travel likely)RecruitingPHASE2

Palo Alto, United States · Portland, United States

Therapeutic RSK1 Targeting in Myelofibrosis

Myelofibrosis

Abroad (travel likely)RecruitingPHASE1

St Louis, United States